Lee JJ - Search Results

1

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. San-Miguel JF, et al. Among authors: lee jh, lee jj. Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18. Lancet Oncol. 2014. PMID: 25242045 Clinical Trial.

2

CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas.

Kim JG, Sohn SK, Chae YS, Kim DH, Baek JH, Lee KB, Lee JJ, Chung IJ, Kim HJ, Yang DH, Lee WS, Joo YD, Sohn CH. Kim JG, et al. Among authors: lee kb, lee ws, lee jj. Cancer Chemother Pharmacol. 2006 Jul;58(1):35-9. doi: 10.1007/s00280-005-0136-y. Epub 2005 Nov 25. Cancer Chemother Pharmacol. 2006. PMID: 16308699 Clinical Trial.

3

High-dose therapy and autologous stem cell transplantation in Korean patients with aggressive T/NK-cell lymphoma.

Bang SM, Kim YK, Park YH, Sohn SK, Lee JJ, Cho EK, Ryoo BY, Chung IJ, Yoon SS, Kim HJ, Lee JH, Yoon HJ, Park S. Bang SM, et al. Among authors: lee jh, lee jj. Leuk Lymphoma. 2005 Nov;46(11):1599-1604. doi: 10.1080/10428190500215191. Leuk Lymphoma. 2005. PMID: 16334486

4

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.

Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, Sohn SK. Kim DH, et al. Among authors: lee jj. Blood. 2006 Oct 15;108(8):2720-5. doi: 10.1182/blood-2006-01-009480. Epub 2006 Apr 11. Blood. 2006. PMID: 16609067 Free article. Clinical Trial.

5

A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma.

Bang SM, Lee JH, Yoon SS, Park S, Min CK, Kim CC, Suh C, Sohn SK, Min YH, Lee JJ, Kim K, Seong CM, Yoon HJ, Cho KS, Jo DY, Lee KH, Lee NR, Kim CS; Korean Multiple Myeloma Working Party. Bang SM, et al. Among authors: lee nr, lee kh, lee jh, lee jj. Int J Hematol. 2006 May;83(4):309-13. doi: 10.1532/IJH97.A30512. Int J Hematol. 2006. PMID: 16757429

6

New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.

Kim H, Sohn HJ, Kim S, Kim K, Lee JH, Bang SM, Kim DH, Sohn SK, Lee JJ, Suh C. Kim H, et al. Among authors: lee jh, lee jj. Biol Blood Marrow Transplant. 2006 Aug;12(8):837-44. doi: 10.1016/j.bbmt.2006.04.006. Biol Blood Marrow Transplant. 2006. PMID: 16864054 Free article.

7

Pilot remission induction therapy with idarubicin, plus an intensified dose of ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia.

Baek JH, Sohn SK, Kim DH, Kim JG, Yang DH, Kim YK, Lee JJ, Kim HJ. Baek JH, et al. Among authors: lee jj. Acta Haematol. 2007;117(2):109-14. doi: 10.1159/000097386. Epub 2006 Nov 28. Acta Haematol. 2007. PMID: 17135724 Clinical Trial.

8

Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study.

Kim JG, Sohn SK, Chae YS, Cho YY, Yang DH, Lee JJ, Kim HJ, Shin HJ, Chung JS, Cho GJ, Lee WS, Joo YD, Sohn CH, Oh SJ. Kim JG, et al. Among authors: lee ws, lee jj. Cancer Chemother Pharmacol. 2007 Jun;60(1):129-34. doi: 10.1007/s00280-007-0469-9. Epub 2007 Apr 4. Cancer Chemother Pharmacol. 2007. PMID: 17406867 Clinical Trial.

9

Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas.

Lee JJ, Kim DH, Lee NY, Sohn SK, Kim JG, Kim HJ, Do YR, Park YH. Lee JJ, et al. Among authors: lee ny. Br J Haematol. 2007 May;137(4):329-36. doi: 10.1111/j.1365-2141.2007.06570.x. Epub 2007 Apr 4. Br J Haematol. 2007. PMID: 17408400 Free article.

10

Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors.

Chae YS, Sohn SK, Kim JG, Cho YY, Moon JH, Yang DH, Lee JJ, Kim YK, Kim HJ, Shin HJ, Chung JS, Cho GJ. Chae YS, et al. Among authors: lee jj. Am J Hematol. 2008 Aug;83(8):649-53. doi: 10.1002/ajh.21215. Am J Hematol. 2008. PMID: 18528826 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,222 results

Search Page